{"id":"NCT04761627","sponsor":"Amgen","briefTitle":"A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-24","primaryCompletion":"2023-02-28","completion":"2023-02-28","firstPosted":"2021-02-21","resultsPosted":"2024-01-11","lastUpdate":"2024-01-11"},"enrollment":494,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Ustekinumab","otherNames":["StelaraÂ®"]},{"type":"DRUG","name":"ABP 654","otherNames":[]}],"arms":[{"label":"Continued-use Group (Ustekinumab)","type":"ACTIVE_COMPARATOR"},{"label":"Switching Group (Ustekinumab - ABP 654)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Area Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (AUCtau) Between Week 52 and Week 64","timeFrame":"Blood samples were taken pre-dose week 52; and at 2 days, 7 days, 10 days, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after the week 52 dose","effectByArm":[{"arm":"Post-randomization Switching: Ustekinumab RP and ABP 654","deltaMin":5144.4,"sd":45.3},{"arm":"Post-randomization Continued-use: Ustekinumab RP","deltaMin":5768.45,"sd":50.4}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":88,"countries":["United States","Canada","Estonia","Georgia","Germany","Hungary","Latvia","Poland"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":494},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis"]}}